University of Tennessee Health Science Center

Cellworks Biosimulation Study Reveals Biomarkers That Predict Response to Hypomethylating Agents and Patient Survival in MDS

Retrieved on: 
Monday, December 12, 2022
Software, Research, General Health, Pharmaceutical, Data Management, Oncology, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, Other Science, Leukemia Research, HOXA9, Lymphatic system, CEBPA, Software, Biosimulation, Society, Research, Methylation, Disease, Patient, DS, SPI1, Pearson, EZH2, Myelodysplastic syndrome, AML, MDS, Drug combination, Prognosis, Decitabine, City, University of Tennessee Health Science Center, University, DNMT3A, Abstract, Survival, NR, R, MD, Leukemia, Diagnosis, CBL, CBM, UnitedHealth Group, Student, TP53, Sequoia Capital, HMA, ASH, Versata Development Group, Inc. v. SAP America, Inc., Master of Science, Exposition, Chair, NF1, ITGAM, Haematopoietic system, Biomarker, RUNX1, Neuro, GATA1, Blood, Hypomethylating agent, NRAS, Medical imaging, Pharmaceutical industry, Hematology

In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).

Key Points: 
  • In the study, DS predicted HMA response in MDS patients and showed a strong correlation to the treatment efficacy score (ES).
  • This study demonstrates the power of using Cellworks personalized therapy biosimulation to gain insight into individual patient mutanome, drug resistance pathways and novel biomarkers that determine their drug response and resistance to better inform treatment decisions for MDS patients.
  • This study shows that Cellworks personalized therapy biosimulation, which was based on each patients genomic aberrations, reveals a high spectrum of DS among patients with MDS.
  • The Cellworks Platform predicts therapy response for individual patients and patient cohorts using a breakthrough Computational Biology Model (CBM) and biosimulation technology.

The Hockaday School Names Dr. Laura Leathers as New Head of School

Retrieved on: 
Friday, December 2, 2022
Curriculum, Four Cornerstone Model of Emotional Intelligence, History, Learning, Student, Doctor of Philosophy, Woman, Hockaday School, AP, Universite des Sciences Appliquée et Management, Varsity, Head teacher, Administration, University of Tennessee Health Science Center, Upper school, Episcopal School, Parent, University, Salesian School, Chertsey, Mary, mother of Jesus, Union University, Character, Danny Howells, Lafayette College, Faculty, St. Mary's Episcopal School, Class, Science, Education, Love, AP Chemistry, Trustee, Solid Modeling Solutions, Medicine, Athletics, Biochemistry, Engineering, Pharmacology, STEM, School

DALLAS, Dec. 2, 2022 /PRNewswire/ -- The Hockaday School is pleased to announce Dr. Laura Leathers as the next Eugene McDermott Head of School, effective January 1, 2023.

Key Points: 
  • DALLAS, Dec. 2, 2022 /PRNewswire/ -- The Hockaday School is pleased to announce Dr. Laura Leathers as the next Eugene McDermott Head of School, effective January 1, 2023.
  • Prior to her interim role, Dr. Leathers served as Hockaday's Assistant Head of School for Academic Affairs.
  • The selection follows an extensive nationwide search for a new Head of School conducted along with the School's search partner, RG175.
  • "We are thrilled to name Dr. Leathers as the next Head of School," said Nicole Ginsburg Small '91, Chair of the Hockaday Board of Trustees.

Pain Intensity in Sickle Cell Disease

Retrieved on: 
Monday, November 14, 2022
Experimental biology, Prevalence, COMT, University of Tennessee Health Science Center, Experimental Biology and Medicine, African Americans, Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal), Haplotype, National Tainan Junior College of Nursing, DRD3, Publishing, Society, Pain, University, D3, Sickle cell disease, College, Patient, Pharmaceutical industry, Dentistry, Medicine

Pain, characterized by episodes of acute pain, is a hallmark symptom of individuals living with sickle cell disease, resulting in acute health care utilization.

Key Points: 
  • Pain, characterized by episodes of acute pain, is a hallmark symptom of individuals living with sickle cell disease, resulting in acute health care utilization.
  • The goal of this study was to examine the association among haplotypes of COMT and DRD3 single nucleotide polymorphisms with pain intensity and pain-related acute care utilization in sickle cell disease.
  • Identification of genetic contributions to pain may result in a greater understanding of sickle cell disease pain and may lead to improved medical management.
  • Although sickle cell disease was first recognized over 100 years ago, progress in therapies have lagged significantly, with pain continuing to be the hallmark symptom for over 100,000 Americans living with sickle cell disease.

Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Private Securities Litigation Reform Act, MHA, Data collection, Forward-looking statement, ACC (company), Methodist Hospital, U.S. Department of Defense Strategy for Operating in Cyberspace, MPH, Heart failure, Partnership, Knowledge, Prisma Health Richland Hospital, Adoption, Risk, NIH, Technology, Prisma Health, COVID-19, Mortality, EVP, SEC, Volume analysis, Blood volume, University of Tennessee Health Science Center, University, Awareness, Patient, Baptist Hospital, CEO, Critical care, BVA, Industry, American College of Cardiology, FDA, American College, Hospital, Risk management, Pharmaceutical industry

Former Section Chief Nuclear Medicine, ChristianaCare, Newark, Delaware, and James Kreiner, MHA, Director Cardiovascular Operations, Prisma Richland, Columbia, South Carolina.

Key Points: 
  • Former Section Chief Nuclear Medicine, ChristianaCare, Newark, Delaware, and James Kreiner, MHA, Director Cardiovascular Operations, Prisma Richland, Columbia, South Carolina.
  • The webinar panelists will be discussing first-hand how BVA has demonstrated notable improvements in patient outcomes, hospital savings and resource use.
  • Daxor has been a tremendous partner with MedAxiom as we work to transform cardiovascular care and improve heart health.
  • Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation.

RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022

Retrieved on: 
Wednesday, October 26, 2022
Quality of life, Stomach, Doctor of Philosophy, Constipation, Population, Rifabutin, Genetically modified bacteria, PPI, Patient, Feinberg School of Medicine, PAMORA, Division, Amoxicillin, Nasdaq, BID, WHO, University, ITT, World, ACG, Opioid, Ulcerative colitis, University of Tennessee Health Science Center, MALT, Adult, PBPK, World Health Organization, Helicobacter pylori, Clarithromycin, Omeprazole, OIC, American College, FDA, Redhill, QOL, Prescription, Pharmaceutical industry, Vaccine, Dentistry, Gastroenterology, MD, Northwestern University, Naloxegol

RALEIGH, N.C. and TEL-AVIV, Israel, Oct. 26, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the presentation of new data analyses for Talicia®, for the treatment of H. pylori, and Movantik®, for the treatment of opioid -induced constipation (OIC), at the American College of Gastroenterology Annual Meeting (ACG) October 21-26, 2022.

Key Points: 
  • This second Movantik poster evaluated the efficacy of Movantik in providing clinically meaningful symptom improvement, based on the PAC-SYM patient reported outcome, in patients with OIC.
  • In both analyses Movantik was well tolerated and demonstrated a favorable safety profile.
  • Talicia may affect the way other medicines work, and other medicines may affect the way Talicia works.
  • [11] The pivotal Phase 3 study with Talicia demonstrated 84% eradication of H. pylori infection with Talicia vs. 58% in the active comparator arm (ITT analysis, p

Scitech and the Plough Center Announce Manufacturing Agreement

Retrieved on: 
Thursday, October 20, 2022
Therapy, Plough, IND, CGMP, Solution, Patient, Tony Fitzpatrick (artist), SDP, Orphan drug, University, FARMS, University of Tennessee Health Science Center, Business development, GLOBE, Clinical trial, SciTech, Medical device, Pharmaceutical industry, Lymphoma

GROSSE POINTE FARMS, Mich., Oct. 20, 2022 (GLOBE NEWSWIRE) -- SciTech Development is pleased to announce that it has signed a $600K manufacturing agreement with The Plough Center for Sterile Drug Delivery Systems.

Key Points: 
  • GROSSE POINTE FARMS, Mich., Oct. 20, 2022 (GLOBE NEWSWIRE) -- SciTech Development is pleased to announce that it has signed a $600K manufacturing agreement with The Plough Center for Sterile Drug Delivery Systems.
  • The Plough Center will deliver the clinical supply of SciTech's lead cancer drug candidate, ST-001 nanoFenretinide.
  • Earle Holsapple, President of SciTech Development, said, "SciTech chose The Plough Center for their expertise in drug delivery manufacturing in addition to their intimate knowledge of combining and processing nanoparticles.
  • The mission of The Plough Center for Sterile Drug Delivery Solutions is to help patients by expediting efforts to bring innovative, life-saving medicines to market.The Plough Center is a US-FDA registered cGMP sterile drug manufacturing facility owned by the University of Tennessee Health Science Center in Memphis.

FHU Hosts RAM Dental Clinic, Serves 100+ Area Residents

Retrieved on: 
Thursday, October 6, 2022
Time, Tennessee State Guard, Bible, Toothache, Public relations, Education, Volunteering, National Guard Armory, Remote Area Medical, Patient, Methodism, United Methodist Church, Colorado National Guard Armory, Community, University, Student, Dental care, Freed–Hardeman University, Reading, FHU, University of Tennessee Health Science Center, Pain, Health, Percussion section, Triage, Computer data storage, Medicine, Hospital, RAM

HENDERSON, Tenn., Oct. 5, 2022 /PRNewswire-PRWeb/ -- Freed-Hardeman University's Remote Area Medical (RAM®) Chapter made a difference in the lives of approximately 101 individuals by providing services valued at nearly $60,000 during a pop-up dental clinic held Sept. 30 through Oct. 1, 2022, at the National Guard Armory in Henderson.

Key Points: 
  • RAM, FHU's RAM Chapter and a group of campus and community partners organized resources to bring the pop-up clinic to the area.
  • RAM, FHU's RAM Chapter and a group of campus and community partners organized resources to bring the pop-up clinic to the area.
  • RAM's mission is to alleviate suffering and leave patients in a better condition, according to Brad Hutchins, RAM clinic coordinator.
  • RAM delivers free dental, vision and medical services to underserved and uninsured individuals.

Black female excellence takes center stage at St. Jude Spirit of the Dream

Retrieved on: 
Tuesday, October 4, 2022
Children, Aerospace, Manufacturing, Health, Philanthropy, Women, Oncology, Other Philanthropy, Research, Consumer, Science, Tiger, Color, Cancer, African Americans, University of Tennessee Health Science Center, Food, News, ALSAC, History, Sickle cell disease, Hospital, LinkedIn, TikTok, St. Jude Children's Research Hospital, Research, Disease, Walking, Survival, Dream, NCI-designated Cancer Center, The Duchess of Kent Children's Hospital at Sandy Bay, CEO, Twitter, Multimedia, Instagram, National Cancer Center, Pleasure, Hurston-Wright Legacy Award, African, Housing, Child, Quality of life, Program, Patient, National Cancer Institute, Travel, University, Love, Spirit, Woman, Hope, Awareness, Toy, Facebook, Inspiration4, Jude the Apostle

For the first time in its history, the St. Jude Spirit of the Dream event selected women for each of its highest accolades: the St. Jude Spirit of the Dream award and the Legacy Award.

Key Points: 
  • For the first time in its history, the St. Jude Spirit of the Dream event selected women for each of its highest accolades: the St. Jude Spirit of the Dream award and the Legacy Award.
  • Though Greer retired in 2021, she remains committed to the mission of St. Jude.
  • Visit St. Jude Inspire to discover powerful St. Jude stories of hope, strength, love and kindness.
  • Join the St. Jude mission by visiting stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%

Retrieved on: 
Monday, October 3, 2022
ASM, University of Tennessee Health Science Center, BVA, Hospital, Mortality, Physician, CEO, DRG, HF, Patient, Heart failure, Heart Failure Society of America, University, GLOBE, Health insurance

Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation, the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic blood test in reducing hospital length of stay (LOS) for heart failure (HF) patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought together the world’s leading experts in heart failure from September 30th thru October 3rd, 2022, in Washington, DC.

Key Points: 
  • Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 which brought together the worlds leading experts in heart failure from September 30th thru October 3rd, 2022, in Washington, DC.
  • Annual costs for HF treatment are estimated at $30.7 billion and expected to grow to nearly $70 billion by 2030 if we fail to improve on current treatment outcomes.
  • Shorter length of hospital stay has an enormous potential for hospital cost savings as hospitals receive a single block payment under DRG rules of reimbursement.
  • The study titled Length of Stay After Blood Volume Analysis in Hospitalized Heart Failure compared both hospital admission and discharge dates, allowing the calculation of pre- and post-BVA LOS for all patients.

Iridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022

Retrieved on: 
Thursday, September 29, 2022
University of Tennessee Health Science Center, American Academy, AAO, Safety, IOP, Glaucoma, Diabetic retinopathy, MLT, IRIX, FRCSC, Compliance, University of Utah, Retina, Cyclo, Patient, MIGS, Physician, CEO, Surgeon, NASDAQ, TLT, CPT, GLOBE, Intraocular pressure, University, International, Medical imaging, Medical device, Pharmaceutical industry, Dentistry, MD, Ophthalmology

MOUNTAIN VIEW, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, will showcase non-incisional glaucoma treatments, introduce its Sweep Management Software, and host 8 physician presentations at the 2022 American Academy of Ophthalmology (AAO) annual meeting in Chicago, September 30 – October 3.

Key Points: 
  • Glaucoma, comprehensive and retina surgeons will present best practices using Iridex MicroPulse, Endpoint Management and continuous-wave laser technologies at our booth #5139.
  • The Cyclo G6 now provides Sweep Management Software, which empowers surgeons to customize each MicroPulse TLT treatment to achieve optimal results for a wide range of glaucoma patients.
  • Surgeons set the power, the sweep duration, and the number of sweeps in a specific treatment desired for each patient.
  • Additionally, new audible tones help the physician meter their sweep speed to aid accurate dosing and clinical results.